These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12235257)

  • 21. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.
    Heravi M; Rachid Z; Goudarzi A; Schlisser A; Jean-Claude BJ; Radzioch D; Muanza TM
    Anticancer Drugs; 2009 Sep; 20(8):659-67. PubMed ID: 19581798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.
    Kelloff GJ; Fay JR; Steele VE; Lubet RA; Boone CW; Crowell JA; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):657-66. PubMed ID: 8824370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24.
    Banerjee R; Huang Y; McNamee JP; Todorova M; Jean-Claude BJ
    J Pharmacol Exp Ther; 2010 Jul; 334(1):9-20. PubMed ID: 20348204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
    J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
    Mishani E; Abourbeh G; Jacobson O; Dissoki S; Ben Daniel R; Rozen Y; Shaul M; Levitzki A
    J Med Chem; 2005 Aug; 48(16):5337-48. PubMed ID: 16078851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways.
    Huang L; Watanabe M; Chikamori M; Kido Y; Yamamoto T; Shibuya M; Gotoh N; Tsuchida N
    Oncogene; 2006 Oct; 25(49):6457-66. PubMed ID: 16702953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
    Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
    Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
    Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
    Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer.
    Fang Y; Qiu Q; Domarkas J; Larroque-Lombard AL; Rao S; Rachid Z; Gibbs BF; Gao X; Jean-Claude BJ
    Prostate; 2012 Sep; 72(12):1273-85. PubMed ID: 22290742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept.
    Banerjee R; Rachid Z; McNamee J; Jean-Claude BJ
    J Med Chem; 2003 Dec; 46(25):5546-51. PubMed ID: 14640561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
    Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
    J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
    Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
    J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity.
    Golabi N; Brahimi F; Huang Y; Rachid Z; Qiu Q; Larroque-Lombard AL; Jean-Claude BJ
    J Pharm Biomed Anal; 2011 Nov; 56(3):592-9. PubMed ID: 21764236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line.
    Qiu Q; Dudouit F; Banerjee R; McNamee JP; Jean-Claude BJ
    Prostate; 2004 Apr; 59(1):13-21. PubMed ID: 14991862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species.
    Todorova MI; Larroque AL; Dauphin-Pierre S; Fang YQ; Jean-Claude BJ
    Mol Cancer Ther; 2010 Apr; 9(4):869-82. PubMed ID: 20354119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile.
    Huang Y; Rachid Z; Peyrard L; Senhaji Mouhri Z; Williams C; Jean-Claude BJ
    Chem Biol Drug Des; 2015 Feb; 85(2):153-62. PubMed ID: 25092264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo biodistribution of ZRS1, a stabilized type I N-acetoxymethyl carbamate-containing combi-molecule.
    Golabi N; Rachid Z; Qiu Q; Huang Y; Jean-Claude BJ
    Drug Metab Lett; 2011 Apr; 5(2):141-9. PubMed ID: 21457144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
    Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.